BXRX News and Press, Baudax Bio Inc. From 03/27/23

2023-03-27 12:09:23 ET Nano-cap biotech Baudax Bio ( NASDAQ: BXRX ) ended a six-day losing streak on Monday in reaction to promising data from a Phase 2 trial for its experimental neuromuscular blocking agent BX1000 in patients undergoing elective surgery. Citing a second ...

41 Subjects Meet Criteria for Good or Excellent Intubation Conditions at 60 Seconds Top Line Results Expected Late April/Early May MALVERN, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovat...

2023-03-17 08:33:13 ET Diebold Nixdorf DBD -28% on liquidity concerns . Sarepta Therapeutics SRPT -18% on FDA advisory meeting for its muscular dystrophy treatment . ThermoGenesis ( THMO ) -19% . First Republic Bank FRC -15% after suspending d...

2023-03-16 13:08:25 ET Gainers: Genelux ( GNLX ) +49% . PureCycle Technologies ( PCT ) +46% . Baudax Bio ( BXRX ) +35% . Lipella Pharmaceuticals  ( LIPO ) +32% . Corbus Pharmaceuticals Holdings ( CRBP ) +27% . EverCommer...

Baudax Bio press release ( NASDAQ: BXRX ): Q4 GAAP EPS of -$12.33 misses by $2.57 . Revenue of $0.31M (-22.5% Y/Y). As of December 31, 2022, Baudax had cash and cash equivalents of $5.3 million. Shares +3.36% PM. For further details see: Baudax Bio GA...

Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion of Study Enrollment Expected Q1 2023, Top Line Results Expected Early Q2 2023 BX2000 Dose Escalation Study Progressing ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips What caused Baudax Bio (NASDAQ: BXRX ) stock to double earlier today? The catalyst was undoubtedly this morning’s announcement concerning a Phase 2 clinical trial of Baudax Bio’s novel product, BX1000. The r...

Baudax Bio ( NASDAQ: BXRX ) added ~70% pre-market Tuesday after announcing a positive outcome in its first interim analysis for Phase 2 trial for experimental neuromuscular blocking agent BX1000 in patients undergoing elective surgery. The trial is designed to evaluate the neuromu...

MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (...

Baudax Bio ( NASDAQ: BXRX ) said in a Dec. 30, 2022 SEC filing that it eliminated its commercial personnel for its first commercial product, pain drug Anjeso (IV meloxicam). The company added that on Dec. 28, 2022, the discontinuation of sale of Anjeso was acknowledged b...